GI Clinical Research 2002-2003: The Year in Review

Clinical Gastroenterology and Hepatology

Volumn 1, Issue 6, 2003, Pages 415-420

  Camilleri, Michael ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA2A INTERFERON; ALPHA4 INTEGRIN; AZATHIOPRINE; BCR ABL PROTEIN; CHIMERIC ANTIBODY; CORTICOSTEROID; HYDROCORTISONE; IMATINIB; INFLIXIMAB; LANSOPRAZOLE; MERCAPTOPURINE; METHOTREXATE; NAPROXEN; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIBODY RESPONSE; APOPTOSIS; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CLINICAL RESEARCH; CLINICAL TRIAL; COLON ADENOMA; COLORECTAL CANCER; CROHN DISEASE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; ERADICATION THERAPY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TUMOR; GENE ACTIVITY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; LEUKAPHERESIS; ONCOGENE; PEPTIC ULCER BLEEDING; PRIMARY PREVENTION; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SECONDARY PREVENTION; STOMACH CANCER; TREATMENT OUTCOME; TUMOR VOLUME; ULCERATIVE COLITIS; VIRUS LOAD; VIRUS REPLICATION;

EID: 0242610327     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-3565(03)00220-9     Document Type: Review

References (20)

1. Lynch KL, Ahnen DJ, Byers T, Weiss DG, Lieberman DA, the Veterans Affairs Cooperative Study Group #380. Do first degree relatives of patients with colorectal adenomas have an increased prevalence of colorectal cancer? Clin Gastroenterol Hepatol 2003;1:96-102.
2. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI., Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-899.
3. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-890.
4. Imperiale TF. Aspirin and the prevention of colorectal cancer. N Engl J Med 2003;348:879-880.
5. Kiesslich R, Fritsch J, Holtmann M, Koehler HH, Stolte M, Kanzler S, Nafe B, Jung M, Galle PR, Neurath MF. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003;124:880-888.
6. Lai KC, Lam SK, Chu KM, Wong BCY, Hui WM, Hu WHC, Lau GKK, Wong WM, Yuen MF, Chan AOO, Lai CL, Wong J. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002;346:2033-2038.
7. Chan FKL, Chung SCS, Suen BY, Lee YT, Leung WK, Leung VKS, Wu JCY, Lau JYW, Hui Y, Lai MS, Chan HLY, Sung JJY. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-973.
8. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-789.
9. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJH. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-1405.
10. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-1549.
11. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-608.
12. Farrell RJ, Alsahli M, Jeen Y-T, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003;124:917-924.
13. von Andrian UH, Engelhardt B. α4 Integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003;348:68-72.
14. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnálek P, Zádorová Z, Palmer T, Donoghue S, the Natalizumab Pan-European Study Group. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32.
15. Hanai H, Watanabe F, Takeuchi K, Iida T, Yamada M, Iwaoka Y, Saniabadi A, Matsushita I, Sato Y, Tozawa K, Arai H, Furuta T, Sugimoto K, Bjarnason I. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol 2003;1:28-35.
16. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang T-T, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL, The Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-807.
17. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Pegin-terferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
18. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
19. Savage DG, Antman KH. Imatinib mesylate: a new oral targeted therapy. N Engl J Med 2002;346:683-693.
20. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CDM, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.